Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WLH-134
- Development stage
- Preclinical
- Lead developer
- Wanle Pharmaceutical
- Modality
- Small Molecules
01
Overview
WLH-134 is a small molecule chemotherapy agent currently under development by Shenzhen Wanle Pharmaceutical. It is part of a series of oncology candidates (including WLH-127, WLH-130, WLH-132, and WLH-133) targeting a broad spectrum of malignancies. The development program for WLH-134 focuses on several high-prevalence indications, including bladder cancer, breast cancer, hematologic malignancies such as leukemia and lymphoma, liver cancer, and cancers of the digestive system, specifically gastric and colorectal cancers. While the specific molecular target and clinical phase have not been publicly detailed on the company's pipeline, it is categorized as a chemotherapy drug within their research and development portfolio.
Beyond the preview
Go deeper on WLH-134.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WLH-134.